Cannabis Law and Access in Zimbabwe

Forty-eight hours after Zimbabwe made its cannabis licensing announcement in May 2018, I was in the middle of a 120-kilometre road ride out through the Majura Valley when a colleague texted me about it. I almost came off the bike. Not because the move was shocking in principle , other African nations were already sniffing around industrial hemp , but because of how fast it happened. A country with a long history of strict drug enforcement rewrote part of its regulatory landscape in what felt like a single Cabinet decision. Worth understanding, I thought. Worth tracking.

That was over six years ago. The framework has changed more than once since. This article is a factual account of how Zimbabwean cannabis law is structured, for Australian readers interested in how other jurisdictions approach scheduling, licensing, and access. To be clear up front: none of this is Australian law. Australian cannabis access operates under the Therapeutic Goods Act 1989, the Poisons Standard, and pathways like the Special Access Scheme , covered separately on this site at Special Access Scheme. Zimbabwe is a different sovereign jurisdiction with a different framework entirely.

The 2018 turning point

Zimbabwe's pivot on cannabis came through Statutory Instrument 62 of 2018, issued under the Dangerous Drugs Act [Chapter 15:02]. The instrument created a licensing regime for the cultivation of cannabis for industrial and medicinal purposes. Critically, it did not legalise recreational use. Cannabis for non-licensed, non-medicinal use remained a criminal matter under the Dangerous Drugs Act. The 2018 instrument carved out a specific, tightly governed exception; nothing more.

The Ministry of Health and Child Care, alongside the Medicines Control Authority of Zimbabwe (MCAZ), was designated as the body responsible for issuing licences for medicinal cannabis activities. The Ministry of Lands, Agriculture, Fisheries, Water and Rural Development handles hemp and industrial cultivation licensing. So from day one, Zimbabwe split oversight between two ministries depending on intended use. That bifurcation has created some administrative complexity, more on that in a moment.

What "industrial hemp" means under Zimbabwean law

The 2018 instrument set a THC threshold of 0.3% by dry weight as the boundary between hemp (legal under licence) and cannabis (controlled). That 0.3% figure will look familiar, it mirrors thresholds used in several European jurisdictions and the United States Farm Bill. The molecule at the centre of that distinction, tetrahydrocannabinol (THC), is the principal reason cannabis sits on controlled substances lists globally. Below 0.3%, Zimbabwe treats the plant as an industrial crop. Above it, the Dangerous Drugs Act framework applies.

Hemp licensees could grow for fibre, seed, and; importantly, cannabinoid extraction, provided the extracted material complied with licensing conditions. This opened a pathway for cannabidiol (CBD) production, which attracted significant international commercial interest given Zimbabwe's agricultural capacity, comparatively lower land and labour costs, and favourable growing climate in regions like Mashonaland and Manicaland provinces.

Medicinal cannabis: the MCAZ licensing framework

For medicinal cannabis specifically, the MCAZ administers a separate licences regime. Applications require documentation of intended use, security arrangements, qualified personnel, cultivation or processing site plans, and evidence of Good Manufacturing Practice compliance, a standard that will also be familiar to anyone following Australian regulatory requirements, referenced here at Good Manufacturing Practice.

Zimbabwe joined a group of African nations; including Lesotho (which moved even earlier, in 2017) and South Africa, positioning themselves as cannabis export suppliers to regulated markets in Europe and elsewhere. The MCAZ framework was designed partly with export certification in mind. That is not a criticism of the framework; it is simply an honest reading of the economic incentive structure that shaped it.

Domestic patient access is a different story. As of the time of writing, a formal domestic medicinal cannabis prescription pathway comparable to, say, Australia's Authorised Prescriber scheme does not appear to be fully operationalised for Zimbabwean patients. Licensing has been heavily export-oriented. That gap between licensing infrastructure and domestic patient access is, in my view, a genuine structural weakness in the framework, common across several emerging cannabis jurisdictions that moved quickly on export economics and more slowly on domestic healthcare integration.

Recreational use: still prohibited

This is worth stating plainly because there is sometimes confusion when a country "legalises cannabis" in headlines. Zimbabwe did not legalise recreational cannabis. Personal possession, use, and supply outside the licensed framework remain offences under the Dangerous Drugs Act [Chapter 15:02]. Penalties under that Act include fines and custodial sentences. Enforcement practices vary by region and circumstance, as they do in most jurisdictions, but the legal position is unambiguous.

There is an ongoing policy conversation in Zimbabwe; as in many countries, about decriminalisation of personal use quantities. But as of 2024, no formal legislative change has been enacted on that question. Anyone relying on news headlines suggesting broader legalisation should go back to the primary instrument, not the press release.

The chemistry Zimbabwe is licensing

One thing that strikes me about the Zimbabwean framework is that it is, structurally, compound-agnostic. Licences cover the plant and its derivatives rather than specifying individual cannabinoids by name. This contrasts with approaches like Australia's Poisons Standard, which schedules specific substances, THC as a Schedule 8 controlled drug and low-dose CBD as Schedule 3; with considerable granularity.

That compound-agnostic approach means Zimbabwe's framework, at least in its current form, does not separately regulate minor cannabinoids like CBG or the terpene profile of licensed cultivars. For reference, terpenes, the aromatic compounds that contribute to what some researchers describe as the entourage effect, are not scheduled substances in most jurisdictions, including Australia, but they are relevant to the characterisation of full-spectrum extracts. See full-spectrum for more on that distinction.

Practical licensing realities and the bifurcated ministry problem

The split between the Ministry of Health (medicinal) and the Ministry of Agriculture (industrial/hemp) has created, by most accounts from researchers studying the sector, duplicative reporting requirements and occasional jurisdictional ambiguity for operators whose products could plausibly sit in either category; for instance, a high-CBD hemp extract intended for eventual medicinal formulation.

Whether that is a fixable administrative issue or a structural design flaw probably depends on which ministry you ask. I'd lean toward calling it a design flaw that was baked in from the 2018 urgency to get a framework published quickly. Regulatory coordination problems tend to calcify if left unaddressed, and Zimbabwe's framework is now old enough that a formal review of the ministry split would seem warranted.

What Australian readers should take from this

Zimbabwe's framework is a useful case study in how a country can use existing dangerous drugs legislation as a chassis, carve out a licensing exception via statutory instrument, and get a regulated industry moving without full primary legislation reform. Australia took a broadly comparable path in 2016 via amendments to the Narcotic Drugs Act 1967 and corresponding changes to the Poisons Standard, though the detail, oversight rigour, and domestic access infrastructure differ substantially.

Understanding frameworks like Zimbabwe's also provides context for the global supply chain that can sit behind internationally sourced ingredients. Where a product's cannabinoid material is cultivated, under what licensing regime, and against what GMP standard are all questions that sit upstream of the pharmacokinetics questions that matter to researchers and clinicians, touched on in our pharmacokinetics glossary entry.

None of this constitutes advice about seeking, importing, or using any cannabis product in Australia. That's governed by Australian law. If you're looking at access pathways under Australian regulation, the Special Access Scheme and Authorised Prescriber pages are the right starting points.

Zimbabwe's story is still being written. The infrastructure exists. Whether it develops a genuine domestic patient access dimension; or remains primarily an export licensing apparatus, will be worth watching over the next few years. Trevor the sourdough starter will likely still be going by then, and I'll still be reading the statutory instruments.

Sources

• Statutory Instrument 62 of 2018 (Cannabis Regulations), Veritas Zimbabwe (primary legislative text)
• Cannabis in Southern Africa: A Regional Overview; UNODC Regional Office for Southern Africa, 2022
• Medicines Control Authority of Zimbabwe (MCAZ), Official regulatory body
• Cannabis Cultivation and Production Guidance, Therapeutic Goods Administration (TGA), Australia

, Marcus Hale, Regulatory researcher; TGA & access law